MatriSys Bioscience
MatriSys Bioscience is a clinical-stage biopharmaceutical company developing topical bacteriotherapy products from beneficial skin bacteria to treat chronic inflammatory skin diseases such as atopic dermatitis, acne, Netherton syndrome, and solar keratosis.
- Company typePrivate
- Founded2015
- HeadquartersLa Jolla, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MatriSys Bioscience does
MatriSys Bioscience, Inc. is a privately held, clinical-stage specialty biopharmaceutical company founded in 2015 and based in La Jolla, California, with 1–10 employees. The company is developing a novel class of topical bacteriotherapy products derived from beneficial bacteria isolated from the healthy human skin microbiome, targeting chronic inflammatory skin diseases characterized by microbiome dysbiosis, including atopic dermatitis, acne, Netherton syndrome, and solar/actinic keratoses. Its discovery platform is built on research from the Gallo Laboratory at the University of California San Diego and screens thousands of skin microbes to identify and optimize bacterial strains with defined mechanisms of action, such as the production of lantibiotics that directly kill Staphylococcus aureus.
The company's lead clinical program, MSB-0221, is a topical prescription formulation designed to treat atopic dermatitis via a triple mechanism: antimicrobial activity through lantibiotic production, inhibition of damaging proteases and phenol-soluble modulins via autoinducing peptide (AIP) signaling, and restoration of commensal skin bacteria to prevent recurrent S. aureus colonization. The broader pipeline targets approximately 230 million+ patients globally with dermatological conditions, with a stated goal of reducing reliance on steroids, immunosuppressants, and antibiotics that carry well-known safety and resistance concerns. Scientific founder Rich Gallo, MD, PhD, is a Distinguished Professor and Founding Chairman of Dermatology at UCSD and is credited with discovering antimicrobial peptides in mammalian skin.
Commercially, MatriSys is pre-revenue with no marketed products, no disclosed pricing, and no distribution or payer relationships in the input data. Revenue mechanics will depend on either out-licensing to a larger dermatology commercial player or building a specialty dermatology commercial organization post-approval, with the CEO's prior pharma-exit track record (Agouron→Pfizer, Ardea→AstraZeneca) and the addition of a Chief Business Officer pointing toward a partnering-oriented go-to-market. The company has raised approximately $4.5M in disclosed funding across 2017 and 2021, with additional participation from Mesa Verde Venture Partners and Baker & Eastlack Ventures.
MatriSys Bioscience firmographics
Firmographics- Name
- MatriSys Bioscience
- Legal name
- MatriSys Bioscience, Inc.
- Website
- https://matrisysbio.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MatriSys Bioscience is a clinical-stage biopharmaceutical company developing topical bacteriotherapy products from beneficial skin bacteria to treat chronic inflammatory skin diseases such as atopic dermatitis, acne, Netherton syndrome, and solar keratosis.
- Ownership category
- akta.pro rank
MatriSys Bioscience industry classification
Industry- Product category
- Dermatology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
- akta.pro secondary industry
- Sensitive Skin & Barrier Repair (CRABAAAG)
Keywords
Where MatriSys Bioscience is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Markets served
MatriSys Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others
MatriSys Bioscience product offering
Product offeringCore offering
MatriSys Bioscience is a clinical-stage biopharmaceutical company developing topical prescription bacteriotherapy products derived from beneficial bacteria of the healthy human skin microbiome. Its lead program MSB-0221 targets atopic dermatitis by killing Staphylococcus aureus and restoring skin homeostasis, with additional pipeline programs for acne, Netherton syndrome, and solar keratosis. All candidates leverage a UCSD Gallo Laboratory-derived discovery platform that screens and optimizes commensal skin strains into topical formulations.
Product overview
MatriSys Bioscience is a biopharmaceutical company developing a novel class of bacteriotherapy products derived from beneficial bacteria of the healthy human skin microbiome. The company's lead product is MSB-0221, a clinical-stage program for Atopic Dermatitis treatment. The broader pipeline includes therapeutic candidates for Acne, Netherton Syndrome, and Solar Keratosis. All programs are built on a discovery platform that screens and optimizes beneficial bacteria strains for topical prescription formulations that restore skin homeostasis and combat microbiome dysbiosis.
Differentiator
Problem solved
Functional benefit
Products and services
- MSB-0221 Topical prescription bacteriotherapy for Atopic Dermatitis (AD) that uses beneficial bacteria to restore the commensal skin microbiome, kill or inhibit Staphylococcus aureus, inhibit aggressive proteases and PSMs, and improve skin immune and barrier dysfunction without the skin-thinning and safety liabilities of steroids or immunosuppressants.
- Bacteriotherapy Discovery Platform Skin microbiome discovery platform, rooted in UCSD Gallo Laboratory research, that screens thousands of microbes on the skin to identify beneficial bacteria that can treat skin disorders and then optimizes selected strains for clinical development of topical prescription formulations.
- Acne Bacteriotherapy Program Topical bacteriotherapy program targeting acne by using the healthy skin microbiome to control Cutibacterium acnes and modulate innate and adaptive immune homeostasis, as an alternative to antibiotic-based acne therapies.
- Netherton Syndrome Bacteriotherapy Program Pipeline program that applies microbiome-targeting technology derived from skin-barrier-microbiome interaction studies to address microbiome abnormalities associated with severity of Netherton Syndrome (SPINK5 mutation).
- Solar Keratosis Bacteriotherapy Program Pipeline bacteriotherapy program targeting Solar Keratosis / Actinic Keratoses as a non-surgical treatment alternative to Mohs surgery for the removal of affected areas.
Companies that use MatriSys Bioscience
Customer profileSegments4 records
Ideal customer profiles1 record
MatriSys Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
MatriSys Bioscience partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights5 records
MatriSys Bioscience competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
MatriSys Bioscience social profiles
Digital presenceMatriSys Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
MatriSys Bioscience leadership team
Management profileNumber of profiles
Profiles6 records
MatriSys Bioscience funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MatriSys Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MatriSys Bioscience
What does MatriSys Bioscience do?
MatriSys Bioscience is a clinical-stage biopharmaceutical company developing topical prescription bacteriotherapy products derived from beneficial bacteria of the healthy human skin microbiome. Its lead program MSB-0221 targets atopic dermatitis by killing Staphylococcus aureus and restoring skin homeostasis, with additional pipeline programs for acne, Netherton syndrome, and solar keratosis. All candidates leverage a UCSD Gallo Laboratory-derived discovery platform that screens and optimizes commensal skin strains into topical formulations.
Is MatriSys Bioscience a public or private company?
MatriSys Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was MatriSys Bioscience founded?
MatriSys Bioscience was founded in 2015. It employs 1 to 10 people.
Where is MatriSys Bioscience based?
MatriSys Bioscience is headquartered in La Jolla, United States, in the North America region.
Does MatriSys Bioscience have an API?
No public API is recorded for MatriSys Bioscience.
What industry is MatriSys Bioscience in?
MatriSys Bioscience's product category is Dermatology Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of CRABAAAG, Sensitive Skin & Barrier Repair. Its NAICS code is 325414 and its SIC code is 2836.